Daxor Corporation (NASDAQ:DXR) Short Interest Up 93.5% in August

Daxor Corporation (NASDAQ:DXR) was the target of a large increase in short interest in August. As of August 31st, there was short interest totaling 592 shares, an increase of 93.5% from the August 15th total of 306 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 3,474 shares, the days-to-cover ratio is currently 0.2 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “hold (c)” rating on shares of Daxor in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy”.

Daxor Stock Down 1.1%

Shares of DXR traded down $0.12 on Tuesday, hitting $11.15. The company’s stock had a trading volume of 15,848 shares, compared to its average volume of 9,700. Daxor has a fifty-two week low of $8.56 and a fifty-two week high of $14.76. The company has a 50 day moving average price of $10.45 and a 200 day moving average price of $10.43.

Institutional Trading of Daxor

Several large investors have recently made changes to their positions in the business. Aristides Capital LLC acquired a new stake in shares of Daxor in the first quarter valued at $403,000. Susquehanna International Group LLP raised its holdings in shares of Daxor by 97.7% in the second quarter. Susquehanna International Group LLP now owns 27,131 shares of the company’s stock valued at $275,000 after buying an additional 13,411 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in Daxor during the 1st quarter worth about $245,000. Nano Cap New Millennium Growth Fund L P acquired a new position in Daxor during the 4th quarter worth about $184,000. Finally, Crescent Grove Advisors LLC bought a new stake in Daxor during the 1st quarter worth about $104,000. Institutional investors own 1.34% of the company’s stock.

About Daxor

Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.